Patents Assigned to Delinia, Inc.
  • Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
    Patent number: 11535657
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: December 27, 2022
    Assignee: Delinia, Inc.
    Inventor: Jeffrey Greve
  • MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20220112260
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 14, 2022
    Applicant: Delinia, Inc.
    Inventor: Jeffrey Greve
  • MULTIVALENT REGULATORY T CELL MODULATORS
    Publication number: 20210403579
    Abstract: This disclosure provides compounds that contain an IL-2 receptor-binding domain and an ST2-binding domain, e.g. an antibody or fragment thereof that specifically binds ST2. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding domain and an ST2-binding domain.
    Type: Application
    Filed: October 30, 2019
    Publication date: December 30, 2021
    Applicant: Delinia, Inc.
    Inventors: Jungmin Kim, Niranjana Nagarajan, Jeffrey Greve
  • IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20210308222
    Abstract: This disclosure provides for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound that comprises an IL-2 receptor-binding moiety. The methods described in the present disclosure provide enhanced pharmacokinetic profiles. The disclosure also provides methods for treating autoimmune disease comprising administering a therapeutically-effective amount of a fusion protein comprising an IL-2 variant protein.
    Type: Application
    Filed: June 22, 2021
    Publication date: October 7, 2021
    Applicant: Delinia, Inc.
    Inventor: Jeffrey Greve
  • IL-2 variants for the treatment of psoriasis
    Patent number: 11077172
    Abstract: This disclosure provides for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound that comprises an IL-2 receptor-binding moiety. The methods described in the present disclosure provide enhanced pharmacokinetic profiles. The disclosure also provides methods for treating autoimmune disease comprising administering a therapeutically-effective amount of a fusion protein comprising an IL-2 variant protein.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: August 3, 2021
    Assignee: DELINIA, INC.
    Inventor: Jeffrey Greve
  • Multivalent regulatory T cell modulators
    Patent number: 11059877
    Abstract: This disclosure provides compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding moiety and an ST2-binding moiety.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: July 13, 2021
    Assignee: Delinia, Inc.
    Inventors: Jeffrey Greve, Jungmin Kim, Niranjana Nagarajan, John Cho
  • MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20210070828
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Application
    Filed: November 6, 2020
    Publication date: March 11, 2021
    Applicant: Delinia, Inc.
    Inventor: Jeffrey Greve
  • MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20210047382
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Application
    Filed: April 7, 2020
    Publication date: February 18, 2021
    Applicant: Delinia, Inc.
    Inventor: Jeffrey Greve
  • Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
    Patent number: 10875901
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: December 29, 2020
    Assignee: Delinia, Inc.
    Inventor: Jeffrey Greve
  • Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
    Patent number: 10774126
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 15, 2020
    Assignee: Delinia, Inc.
    Inventor: Jeffrey Greve
  • Nucleic acid encoding human IL-2 variant
    Patent number: 10766938
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 8, 2020
    Assignee: Delinia, Inc.
    Inventor: Jeffrey Greve
  • MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20200115429
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Application
    Filed: December 30, 2019
    Publication date: April 16, 2020
    Applicant: Delinia, Inc.
    Inventor: Jeffrey Greve
  • MULTIVALENT REGULATORY T CELL MODULATORS
    Publication number: 20200031897
    Abstract: This disclosure provides compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding moiety and an ST2-binding moiety.
    Type: Application
    Filed: October 17, 2019
    Publication date: January 30, 2020
    Applicant: Delinia, Inc.
    Inventors: Jeffrey Greve, Jungmin Kim, Niranjana Nagarajan, John Cho
  • MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20190375812
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Application
    Filed: January 17, 2019
    Publication date: December 12, 2019
    Applicant: Delinia, Inc.
    Inventor: Jeffrey Greve
  • Multivalent regulatory T cell modulators
    Patent number: 10472405
    Abstract: This disclosure provides compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding moiety and an ST2-binding moiety.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: November 12, 2019
    Assignee: Delinia, Inc.
    Inventors: Jeffrey Greve, Jungmin Kim, Niranjana Nagarajan, John Cho
  • MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20190202882
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Application
    Filed: March 13, 2019
    Publication date: July 4, 2019
    Applicant: Delinia, Inc.
    Inventor: Jeffrey Greve
  • MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20190202881
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Application
    Filed: March 13, 2019
    Publication date: July 4, 2019
    Applicant: Delinia, Inc.
    Inventor: Jeffrey Greve
  • MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20190153058
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Application
    Filed: February 5, 2019
    Publication date: May 23, 2019
    Applicant: Delinia, Inc.
    Inventor: Jeffrey Greve
  • Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
    Patent number: 10294287
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: May 21, 2019
    Assignee: Delinia, Inc.
    Inventor: Jeffrey Greve
  • Modified IL-2 variants that selectively activate regulatory T cells
    Patent number: 10035836
    Abstract: The invention described herein is a novel IL-2 protein with selective agonist activity for Regulatory T cells and with an additional amino acid substitution that enable chemical conjugation with Polyethyene Glycol (PEG) that increase circulating half-life compared to the IL-2 selective agonist alone. A preferred IL-2 selective agonist variant is IL2/N88R/C125S/D109C.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: July 31, 2018
    Assignee: Delinia, Inc.
    Inventor: Jeffrey Greve